Difference between revisions of "Center for Medicine in the Public Interest"
Jump to navigation
Jump to search
(Stub) |
m (Text replacement - ", Washington, D.C." to ", Washington DC") |
||
| Line 52: | Line 52: | ||
Until at least 2006 the CMPI published an advisory board.<ref>CMPI [http://web.archive.org/web/20060113193713/www.rxcmpi.org/board/index.html CMPI Advisory board], retrieved from the Internet Archive of 13 January 2006, accessed 25 may 2010</ref> | Until at least 2006 the CMPI published an advisory board.<ref>CMPI [http://web.archive.org/web/20060113193713/www.rxcmpi.org/board/index.html CMPI Advisory board], retrieved from the Internet Archive of 13 January 2006, accessed 25 may 2010</ref> | ||
====January 2006==== | ====January 2006==== | ||
| − | *[[Joesph L. Bast]] President and CEO, The [[Heartland Institute]], Chicago, IL | [[John E. Calfee]] Senior Fellow, [[American Enterprise Institute]], Washington | + | *[[Joesph L. Bast]] President and CEO, The [[Heartland Institute]], Chicago, IL | [[John E. Calfee]] Senior Fellow, [[American Enterprise Institute]], Washington DC | [[Joseph A. DiMasi]], Ph.D. Director of Economic Analysis, [[Tufts Center for the Study of Drug Development]], Tufts University, Boston, MA | [[Helen Disney]] Director, [[Stockholm Network]], London, England | [[Robert Goldberg]] Senior Fellow Manhattan Institute | [[John R. Graham]] Director for Healthcare Studies Pacific Research Institute | [[John Kamp]] Executive Director, [[Coalition for Healthcare Communication]] | [[Sam Kazman]] General Counsel, [[Competitive Enterprise Institute]] | [[Thomas T. Kubic]] Executive Director [[Pharmaceutical Security Institute]] | Dr. [[Merrill Mathews, Jr.]] Resident Scholar, [[Institute for Policy Innovation]] Director, [[Council for Affordable Health Insurance]] | [[David McIntosh]] Attorney, [[Mayer, Brown, Rowe & Maw]] LLP, Washington DC | [[Henry I. Miller]] Research Fellow [[Hoover Institution]] | [[Julian Morris]] Director, [[International Policy Network]], London | [[Sally C. Pipes]] President and CEO [[Pacific Research Institute]] | [[Peter J. Pitts]] Senior Fellow for Healthcare Studies [[Pacific Research Institute]] Senior Vice President for Health Affairs [[Manning, Selvage & Lee]] | [[Stephen Pollard]] Senior Fellow at the [[Centre for the New Europe]], Brussels, Belgium | [[William Roper]] CEO, University of North Carolina Health Care System | [[Ellen V. Sigal]], Ph.D. Founder and Chairperson, [[Friends of Cancer Research]] | [[Samuel C. Silverstein]], M.D. John C. Dalton Professor and Chairman, Department of Physiology and Cellular Biophysics, Columbia University Professor of Medicine, College of Physicians and Surgeons, Columbia University | [[Philip Stieg]], M.D. Professor and Chairman, Department of Neurological Surgery, Weill Medical College Neurosurgeon-in-Chief, New York-Presbyterian Hospital | [[Daniel E. Troy]] Former Chief Counsel of the [[Food and Drug Administration]] (FDA) Partner in the Washington, New York Offices of [[Sidley Austin Brown & Wood]] | [[Grace Marie Turner]] President, The [[Galen Institute]] | [[Ben Zycher]] Senior Fellow in Economics, [[Pacific Research Institute]] Adjunct scholar, [[Cato Institute]], [[Claremont Institute]] |
====??==== | ====??==== | ||
*[[Joesph L. Bast]] President and CEO, The [[Heartland Institute]], Chicago, IL | *[[Joesph L. Bast]] President and CEO, The [[Heartland Institute]], Chicago, IL | ||
| − | *[[John E. Calfee]] Senior Fellow, [[American Enterprise Institute]], Washington | + | *[[John E. Calfee]] Senior Fellow, [[American Enterprise Institute]], Washington DC |
*[[Joseph A. DiMasi]], Ph.D. Director of Economic Analysis, [[Tufts Center for the Study of Drug Development]], Tufts University, Boston, MA | *[[Joseph A. DiMasi]], Ph.D. Director of Economic Analysis, [[Tufts Center for the Study of Drug Development]], Tufts University, Boston, MA | ||
*[[Helen Disney]] Director, [[Stockholm Network]], London, England | *[[Helen Disney]] Director, [[Stockholm Network]], London, England | ||
| Line 62: | Line 62: | ||
*[[Sam Kazman]] General Counsel, [[Competitive Enterprise Institute]] | *[[Sam Kazman]] General Counsel, [[Competitive Enterprise Institute]] | ||
*Dr. [[Merrill Mathews]], Jr. Resident Scholar, [[Institute for Policy Innovation]] Director, [[Council for Affordable Health Insurance]] | *Dr. [[Merrill Mathews]], Jr. Resident Scholar, [[Institute for Policy Innovation]] Director, [[Council for Affordable Health Insurance]] | ||
| − | *[[David McIntosh]] Attorney, [[Mayer, Brown, Rowe & Maw]] LLP, Washington | + | *[[David McIntosh]] Attorney, [[Mayer, Brown, Rowe & Maw]] LLP, Washington DC |
*[[Julian Morris]] Director, [[International Policy Network]], London | *[[Julian Morris]] Director, [[International Policy Network]], London | ||
*[[Tomas J. Philipson]] Professor, The Harris School, Chicago, IL | *[[Tomas J. Philipson]] Professor, The Harris School, Chicago, IL | ||
Revision as of 18:57, 20 October 2016
 Center for Medicine in the Public Interest  (Astroturf)    | |
|---|---|
| Founder |  Big pharma |
| Type | think tank |
| Interests | vaccines |
The Center for Medicine in the Public Interest (CMPI) claims to be a ‘nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered.’ It offers ‘the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness. [1] The director of the Stockholm Network (SN), Helen Disney, used to sit on its now defunct advisory board along with representatives from two think tanks who are part of the SN: International Policy Network (Julian Morris) and Centre for the New Europe (Stephen Pollard).[2] The director of communications at Pfizer Catherine Barr Windels is also on the CPMI board.[3]
The CPMI has been accused of being an 'astroturf' organisation that receives its funding from pharmarceutical companies[4][5]. According to the Washington Post:
- The Center for Medicine in the Public Interest (CMPI) is a New York-based think tank headed by Peter Pitts, a former Food and Drug Administration official who appears frequently on newscasts condemning Democratic health-care proposals. CMPI is an offshoot of the San Francisco-based Pacific Research Institute, which has received foundation grants over the years from Philip Morris, Pfizer and the Pharmaceutical Research and Manufacturers of America, according to public records.
- While serving as president of CMPI, Pitts also works as the global health-care chief at Porter Novelli, a New York public relations firm whose clients include Johnson & Johnson, GlaxoSmithKline, Wyeth and Pfizer. He acknowledges that CMPI also receives money from the pharmaceutical industry, which is supporting reform legislation in exchange for a White House promise to limit cuts.[6]
The CPMI was an offshoot of the Pacific Research Institute which Rachel Maddow describes as 'a famous pro-tobacco ostensibly grassroots corporate front group that was funded by Philip Morris'.[7]
Contents
Funding and disambiguation
The Center for Medicine in the Public Interest should not to be confused with the Center for Science in the Public Interest (CSPI). The two are completely unrelated, despite their very similar sounding names. The CSPI is a non profit public interest group, while the CMPI takes corporate funding.
CSPI says it does not accept funding from corporations or government; instead it is funded by individual donors, foundation grants, and subscriptions to its newsletter.[8]
CMPI, on the other hand, stated on a 2005 version of its website that it accepted corporate funding:
- Its contributors consist primarily of foundations and individuals, with some corporate support, as described in its 2004 annual report.
- PRI solicits and accepts donations from corporations in the health care industry. In order to avoid conflicts of interest, PRI staff and external authors adhere to a Code of Practice.[9]
CMPI has also been funded in part by the pharmaceutical industry. According to Politico.com, CMPI`s biggest contributors in 2006 were the drug maker Pfizer and PhRMA, the drug industry`s trade group.[10]
US Health care reform debate
CMPI was 'a big player' in the U.S. anti-health reform movement in late 2009. They sponsored anti-Obama tea party protests and organized a 'U.S. Policymakers' series that hosted anti-health reform interviews with a 'not-so-broad range of Republican lawmakers, including Michele Bachmann, Joe Wilson, Jim DeMint, David Vitter'. They also produced 'a number of anti-health reform online ads and video and even anti-health reform video games'.[11]
Porter Novelli, the PR firm that employs Peter Pitts who heads CMPI, 'helped that industry kill the Patients Bill of Rights way back in 1994', arguing that it was part of a 'big government agenda', the same arguments used to dicredit the US Healthcare reforms in 2009.[12]
People
Board of Directors
- Gad Berdugo, General Partner, Explorium Capital LLC
- Fred Goodwin, M.D. Professor of Psychiatry, The George Washington University Medical Center.
- Steven Sammut, Lecturer, Wharton School, the Law School and the School of Engineering and Applied Science of the University of Pennsylvania
- Mark Thornton, M.D., Ph.D. Chairman and President, Sarcoma Foundation of America
- Michael Weber, M.D. Professor of Medicine SUNY Downstate College of Medicine, Brooklyn, New York
- Catherine Barr Windels, Principle, OnPoint Strategies, LLC (formerly of Pfizer[13]
Founders
- Peter J. Pitts – President of CMPI and Partner/Director of Global Healthcare at Porter Novelli
- Robert Goldberg - Vice President and Director of Programs at CMPI
CMPI Advisory Board (no longer in existence)
Until at least 2006 the CMPI published an advisory board.[14]
January 2006
- Joesph L. Bast President and CEO, The Heartland Institute, Chicago, IL | John E. Calfee Senior Fellow, American Enterprise Institute, Washington DC | Joseph A. DiMasi, Ph.D. Director of Economic Analysis, Tufts Center for the Study of Drug Development, Tufts University, Boston, MA | Helen Disney Director, Stockholm Network, London, England | Robert Goldberg Senior Fellow Manhattan Institute | John R. Graham Director for Healthcare Studies Pacific Research Institute | John Kamp Executive Director, Coalition for Healthcare Communication | Sam Kazman General Counsel, Competitive Enterprise Institute | Thomas T. Kubic Executive Director Pharmaceutical Security Institute | Dr. Merrill Mathews, Jr. Resident Scholar, Institute for Policy Innovation Director, Council for Affordable Health Insurance | David McIntosh Attorney, Mayer, Brown, Rowe & Maw LLP, Washington DC | Henry I. Miller Research Fellow Hoover Institution | Julian Morris Director, International Policy Network, London | Sally C. Pipes President and CEO Pacific Research Institute | Peter J. Pitts Senior Fellow for Healthcare Studies Pacific Research Institute Senior Vice President for Health Affairs Manning, Selvage & Lee | Stephen Pollard Senior Fellow at the Centre for the New Europe, Brussels, Belgium | William Roper CEO, University of North Carolina Health Care System | Ellen V. Sigal, Ph.D. Founder and Chairperson, Friends of Cancer Research | Samuel C. Silverstein, M.D. John C. Dalton Professor and Chairman, Department of Physiology and Cellular Biophysics, Columbia University Professor of Medicine, College of Physicians and Surgeons, Columbia University | Philip Stieg, M.D. Professor and Chairman, Department of Neurological Surgery, Weill Medical College Neurosurgeon-in-Chief, New York-Presbyterian Hospital | Daniel E. Troy Former Chief Counsel of the Food and Drug Administration (FDA) Partner in the Washington, New York Offices of Sidley Austin Brown & Wood | Grace Marie Turner President, The Galen Institute | Ben Zycher Senior Fellow in Economics, Pacific Research Institute Adjunct scholar, Cato Institute, Claremont Institute
??
- Joesph L. Bast President and CEO, The Heartland Institute, Chicago, IL
- John E. Calfee Senior Fellow, American Enterprise Institute, Washington DC
- Joseph A. DiMasi, Ph.D. Director of Economic Analysis, Tufts Center for the Study of Drug Development, Tufts University, Boston, MA
- Helen Disney Director, Stockholm Network, London, England
- John Kamp Executive Director, Coalition for Healthcare Communication
- Sam Kazman General Counsel, Competitive Enterprise Institute
- Dr. Merrill Mathews, Jr. Resident Scholar, Institute for Policy Innovation Director, Council for Affordable Health Insurance
- David McIntosh Attorney, Mayer, Brown, Rowe & Maw LLP, Washington DC
- Julian Morris Director, International Policy Network, London
- Tomas J. Philipson Professor, The Harris School, Chicago, IL
- Stephen Pollard Senior Fellow at the Centre for the New Europe, Brussels, Belgium
- William Roper CEO, University of North Carolina Health Care System
- Ellen V. Sigal, Ph.D. Founder and Chairperson, Friends of Cancer Research
- Samuel C. Silverstein, M.D. John C. Dalton Professor and Chairman, Department of Physiology and Cellular Biophysics, Columbia University Professor of Medicine, College of Physicians and Surgeons, Columbia University
- Philip Stieg, M.D. Professor and Chairman, Department of Neurological Surgery, Weill Medical College Neurosurgeon-in-Chief, New York-Presbyterian Hospital
- Daniel E. Troy Former Chief Counsel of the Food and Drug Administration (FDA) Partner in the Washington, New York Offices of Sidley Austin Brown & Wood
- Grace Marie Turner President, The Galen Institute
- Ben Zycher Senior Fellow in Economics, Pacific Research Institute Adjunct scholar, Cato Institute, Claremont Institute
Publications and Affiliations
- On 20 September 2005, the CMPI released a report called 21ST CENTURY HEALTH CARE TERRORISM: THE PERILS OF INTERNATIONAL DRUG COUNTERFEITING with the Pacific Institute. It was authored by Peter Pitts, founder of CMPI, along with Michael Tew and Alexandra Preate from Capital HQ. [15]
Many thanks to our Patrons who cover ~2/3 of our hosting bill. Please join them if you can.
References
- ↑ CMPI. CMPI: Mission Statement Accessed 19 April 2010./
- ↑ Centre for Medicine in the Public Interest, CMPI Advisory Board, Centre for Medicine in the Public Interest, 13-January-2006, Accessed vi web archive 25-May-2010
- ↑ CPMI Board of Directors, About Us, Centre for Medicine in the Public Interest, Accessed 24-May-2010
- ↑ Peter Hart, Fear & Favor 2008; Financial woes accelerate corporate pressure in the newsroom, Extra!, April 2009
- ↑ Shannon Brownlee and Jeanne Lenzer, Doctor's Fees, Slate Magazine, 21-November-2008
- ↑ Dan Eggen, Funding for health-care interest groups often fuzzy, Washington Post, 7-January-2010
- ↑ Rachel Maddow, The Rachel Maddow Show, MSNBC, 18-November-2009, 9PM EST
- ↑ CSPI's Funding Sources, CSPI website, acc 21 Apr 2010
- ↑ About Center for Medicines in the Public Interest, CMPI website, archived version copyrighted 2005, accessed in web archive 21 Apr 2010
- ↑ Rachel Maddow, The Rachel Maddow Show, MSNBC, 18-November-2009, 9PM EST
- ↑ Rachel Maddow, The Rachel Maddow Show, MSNBC, 18-November-2009, 9PM EST
- ↑ Rachel Maddow, The Rachel Maddow Show, MSNBC, 18-November-2009, 9PM EST
- ↑ CPMI Board of Directors, About Us, Centre for Medicine in the Public Interest, Accessed 24-May-2010
- ↑ CMPI CMPI Advisory board, retrieved from the Internet Archive of 13 January 2006, accessed 25 may 2010
- ↑ Peter Pitts, Michael Tew and Alexandra Preate. 20 September 2005. 21ST CENTURY HEALTH CARE TERRORISM: THE PERILS OF INTERNATIONAL DRUG COUNTERFEITING Accessed 19 April 2010.
